Kidney cancer: Treatment and Disease management: Biological therapy

The Cancer Specialist Library (CSL) has identified the following resources relevant to this topic area. The CSL performs systematic searches to identify up-to-date, high quality evidence for a given topic. View our

Users should note that the CSL has not performed an in-depth appraisal for each reference but has applied rigorous methods to select them. Where pre-appraisals exist, we link to them. We recommend that a full appraisal is completed using the appropriate check-list provided by the We welcome feedback about resources that we identify, do if you would like to comment.

References:

2008
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma, 2008. New
Update on the Medical Treatment of Metastatic Renal Cell Carcinoma, 2008
Targeted therapy for advanced renal cell carcinoma (Cochrane Review), 2008.
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis, 2008.Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib, 2008.
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis, 2008.


2007
Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline, 2007.
Toxicities associated with the administration of sorafenib, sunitinib and temsirolimus and their management in patients with metastatic renal cell carcinoma, 2007.
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors, 2007.
Sunitinib (Sutent(R)): A novel agent for the treatment of metastatic renal cell carcinoma, 2007.
The role of cytokine therapy in metastatic renal cell cancer, 2007.

2006
Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma, 2006.
Bevacizumab for renal cell carcinoma - advanced, 2006.
Sorafenib tosylate (nexavar) for advanced renal cell carcinoma, 2006.
Sorafenib for the treatment of advanced renal cell carcinoma, 2006


2005
Suntinib for the management of renal cell carcinoma, 2005.
Operative therapy and postoperative adjuvant therapy in patients with renal cancer. Chinese Journal of Evidence-Based Medicine 2005, 5(11):874-8.
Immunotherapy for advanced renal cancer, 2005.


2004
A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renall cell cancer, 2004.


2000
Systematic therapy for renal cell carcinoma, 2000.